Calcific aortic stenosis: Another face of atherosclerosis?

ABSTRACT

Calcific aortic stenosis is not the result of decades of wear and tear alone. Rather, it is being increasingly recognized as an inflammatory, atheromatous, and potentially modifiable disease. Exciting new research suggests that medical therapies may soon be available to retard its progression and reduce the need for surgery.

KEY POINTS

The lesion of calcific aortic stenosis shares histologic similarities with atheromatous coronary artery disease, and its development and progression are linked to various traditional risk factors for atherosclerosis.

For unclear reasons, only about 40% of patients with calcific aortic stenosis also have coronary artery disease, and most people with coronary artery disease do not have calcific aortic stenosis.

Hypertension, smoking, and diabetes mellitus have consistently been linked to the development of aortic stenosis. Endothelial injury or other processes that contribute to coronary disease may play a similar role in calcific aortic stenosis.

In observational studies, aortic stenosis progressed at a slower rate in patients who received statin drugs than in those who did not.

Calcific aortic stenosis has a lot in common with atherosclerotic coronary artery disease. So can lipid-lowering statin drugs stop it?

Historically, calcific aortic stenosis was thought to result from aging and “wear and tear” of the aortic valve.1,2 Hence it was designated “degenerative” or “senile-type.”

This perception is changing. Over the last decade, a growing understanding of the risk factors for calcific aortic stenosis and of its histologic characteristics have led to new insights into how it develops. Investigators have found histologic similarities between the lesion of aortic stenosis and atheromatous coronary artery disease3,4 and have established an association between traditional atherosclerotic risk factors and the development of calcific aortic valve disease.5–14

This condition is the most common reason for valve replacement in the United States,15 and when it is severe it accounts for considerable disease and death, especially in older patients.

Up to now, the only established treatment for symptomatic aortic valve stenosis has been to replace the valve. Newer therapies that may modify or reduce the likelihood of developing aortic valve disease are highly desirable and are currently under investigation.

In this article we summarize what is known about the possible role of lipids, infection, and other risk factors in nonrheumatic calcific aortic sclerosis and stenosis and potential treatments. We use valve “sclerosis” to mean a thickening of the aortic valve leaflets, often with superimposed calcification, whereas valve “stenosis” implies a more advanced situation in which the leaflets stick and do not open normally.
AGING NOT THE ONLY CAUSE

The debate over the pathogenesis of non-rheumatic calcific aortic stenosis (ie, stenosis of a trileaflet aortic valve) dates back to 1904, when Mönckeberg first described dystrophic calcification of the aortic valve. The conventionally accepted hypothesis has been that with age, repeated mechanical stimuli and hemodynamic forces lead to leaflet injury and dystrophic calcification. Although age-related changes in the valve do occur, aging should not be considered synonymous with aortic valve disease, because many elderly people do not develop aortic stenosis. Moreover, over the last decade, studies have linked the development and progression of calcific aortic valve disease to various traditional risk factors for atherosclerosis. Further support for the hypothesis that the condition is not just age-related comes from the work of Otto et al and O’Brien et al, who found that the “early lesion” of aortic stenosis is microscopically similar to atheroma in several ways. Nevertheless, key questions remain: • Nearly 40% of patients with aortic valve stenosis also have significant coronary artery disease, defined as a narrowing of the luminal diameter of an epicardial coronary artery of 70% or more. Why does the disease involve only the aortic valve and spare the coronary arteries in the other 60% of cases? • Conversely, why do most people with coronary artery disease not have aortic valve stenosis, despite similar risk profiles? • Aortic sclerosis is found in approximately 25% of elderly people in the United States, whereas aortic stenosis develops in only 2% to 3% of people older than 75 years. Why is it that most patients with aortic sclerosis do not develop progressive, obstructive aortic valve disease?

LIPIDS, LIPOPROTEINS, AND AORTIC VALVE DISEASE

From small case series to large population-based studies, aortic sclerosis and stenosis have both been repeatedly found to be associated with dyslipidemia, specifically: • Elevated total cholesterol• Elevated low-density lipoprotein (LDL) cholesterol • Elevated triglycerides • Low high-density lipoprotein (HDL) cholesterol. This has not been well studied. One case report described the premature development of aortic stenosis in a young man with Tangier disease, a hereditary condition with markedly low HDL levels; the only other report was a cross-sectional analysis that correlated low HDL levels with aortic sclerosis in an elderly cohort. Elevated lipoprotein(a): Two population-based studies showed that serum lipoprotein(a) levels closely correlate with the presence of aortic sclerosis, independent of LDL levels.

HISTOLOGIC FEATURES

In the 1970s and 1980s, Pomerance and Roberts described calcification of the aortic cusps that was “preceded by lipoid deposition” and shared “the same etiology as the coronary atherosclerotic plaques.” Similarities with coronary disease Otto et al and others elegantly characterized the histologic features of calcific aortic valve disease. On gross inspection, diseased aortic valves have areas of irregular thickening and calcification on the aortic side. Microscopically, all diseased aortic leaflets reveal disruption of the endothelium on the aortic side. This process, similar to what occurs in coronary artery disease, constitutes the initial injury to the leaflet, whereby inflammatory cells and cholesterol can enter. Once the endothelium is disrupted, possibly by mechano-
Aortic valve stenosis: Similar to coronary artery disease

At all stages of the disease, aortic valve lesions show a disrupted basement membrane with subendothelial accumulation of intracellular and extracellular lipids and lipoproteins, and also a chronic inflammatory infiltrate made up of foam cells, non-foam cell macrophages, and T lymphocytes.3,4

Additional evidence comes from patients with familial hypercholesterolemia. People who are homozygous for this trait often have premature coronary disease, but aortic valve disease is another common but under-appreciated feature. In these people, lipids infiltrate the aortic cusps and consequently cause them to thicken and stick together, restricting their

FIGURE 1. Disruption of the endothelium, which also occurs in coronary artery disease, constitutes the initial injury to the leaflet, whereby inflammatory cells and cholesterol can enter. Once the endothelium is disrupted by mechanical stress or other factors, the disease progresses through its various stages of sclerosis and stenosis.
mobility and rendering the valve stenotic.20,21,30,31 Aortic valve cusps from homozygotic patients who undergo aortic valve replacement show significant thickening with foam cell deposition surrounded by dystrophic calcification.31 These findings occur in trileaflet, congenitally normal aortic valves and as early as in the second decade of life.

The regions containing lipoproteins occur at the same location as areas of calcification.4 From the subendothelium, the lesions extend to the leaflet’s central portion, called the fibrosa, and most often involve the base of the leaflet. These findings appear more advanced as the clinical grade of aortic stenosis progresses.

Dissimilarities with coronary disease
Although aortic stenosis and coronary artery lesions share many atheromatous features, there are notable dissimilarities. For example, in aortic valve disease there are fewer smooth muscle cells, and there is more dystrophic calcification. This greater degree of calcification has generated considerable interest in possible specific cellular and, more recently, genetic mechanisms of aortic stenosis.

Osteopontin and other bone proteins have been found in calcified aortic valves.26,32 Mohler et al28 recently reported on the common finding of heterotopic ossification and active bone remodeling in diseased aortic and mitral valves. Lamellar bone was found in 13% of valves with dystrophic calcification.

Recently, Ortlepp et al33 identified a potential genetic marker for the development of calcific aortic stenosis. In a case-control study, subjects with aortic stenosis had a higher prevalence of the B allele of the gene encoding the vitamin D receptor than of the b allele. This polymorphism has been previously associated with greater bone loss34 and lower bone density,35 and these observations led the authors to suggest that the B allele may render a patient more susceptible to dystrophic valvular calcification.

This study may provide a clue to the suggested association between osteoporosis and calcification of the mitral and aortic valves.9,11 The exact interaction between this polymorphism, lipids, and inflammation and its role in the development and progression of aortic valve disease remain unclear.

Hypertension, smoking, and diabetes mellitus are linked to aortic stenosis
Hypertension,6,9,11,22 smoking,7,11 and diabetes mellitus5,6,14 have consistently been linked to the development of aortic stenosis, although their exact disease-promoting actions are unclear. Endothelial injury or other processes at work in coronary disease may play a similar role in calcific aortic stenosis.

Other factors that may be associated with aortic valve disease include:
- Age8–11,22
- Male sex7,11
- Obesity8
- Uremia36
- Elevated calcium37
- Elevated parathyroid hormone9,38
- Osteoporosis9,11
- Paget disease39
- Significant renal failure.36,40
- The high cardiac-output state, which can coexist with Paget disease and renal failure, may also promote the valvular disease process.

Novel risk factors
Not all patients with risk factors for calcific aortic stenosis develop the condition. Conversely, some patients develop the condition despite having only a few risk factors, so yet- unidentified disease-promoting factors may play a role.

Infectious agents, mainly Chlamydia pneumoniae, stirred interest as possible causes of coronary disease and have also been considered as possible causes or promoters of calcific aortic valve disease. Although the data conflict, most studies found C pneumoniae to be more prevalent in diseased aortic valves than in normal aortic valves.41,42

What role this or any other infectious agent plays needs to be better defined. Moreover, whether antibiotic therapy has any effect on slowing the progression of valvular disease is not known.

Elevated homocysteine. Calcific aortic valve disease begins with some form of endothelial injury, and homocysteine can damage the endothelium. Is there a connection?

We recently assessed the association between plasma homocysteine and various
No drug has been shown to alter the natural history of aortic stenosis.
duced in one additional retrospective study in similar patients.\(^50\)

These studies seem to justify a prospective trial to substantiate whether drug therapy with statins slows the progression of aortic stenosis. This is currently in progress.

**FUTURE DIRECTIONS**

New genetic markers, such as the B allele of the vitamin D receptor, may help us to assess an individual's risk of developing aortic valve disease. The role of novel cellular components of diseased valves, such as matrix proteins and mast cells, is an area of increasing interest and research.

Potential markers of disease progression, such as C-reactive protein,\(^55\) may be useful tools in deciding the optimal time for valve surgery in patients with mild aortic disease undergoing open-heart surgery for another condition.

ADDRESS: Brian P. Griffin, MD, Section of Cardiovascular Imaging, F15, Department of Cardiology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44122; e-mail griffib@ccf.org.